The United States has decided to impose sanctions on an Israeli military unit, which the United States had received information regarding to be involved in humanitarian incidents in Palestine.
The United States is set to impose sanctions on the Israel Defense Forces’ most reactionary unit, the Netza Yehuda Battalion, the White House has confirmed, under which the unit will not be able to use American military supplies.
The unit has been accused of human rights violations in Palestine, while Secretary of State Anthony Blanken said that we will reveal the results of the investigation very soon.
The number of ships allowed to pass through the drought-hit Panama Canal each day will be increased thanks to signs of rising water levels, authorities said Monday.
The interoceanic channel is a key transit point for international cargo, but low water levels blamed on climate change and the El Nino phenomenon last year led officials to limit the number of ships using it.
The Panama Canal Authority said it had told clients it would gradually allow up to 32 ships through each day, compared with a limit of 27 announced a month ago.
In 2022, an average of 39 ships are received every day.
“Water management and administration has been very efficient,” canal administrator Ricaurte Vasquez told AFP.
The arrival of the rainy season is also expected to help, he added.
Also read: Panama plans to build a dry canal due to drought
Restrictions on the maximum draft (water depth) of ships passing through the largest locks will be increased in mid-June to 13.71 meters (45 feet), from the previous 13.41, the authority said.
The century-old maritime channel, which normally handles regarding six percent of global maritime trade, uses rainwater stored in two artificial lakes.
The canal – used mainly by customers from the United States, China and Japan – has a lock system for lifting and lowering ships.
For every ship that passes through the canal, 200 million liters of fresh water are released into the sea. (AFP/Z-3)
#Panama #Canal #Ease #Ship #Traffic #Restrictions #Due #Drought
2023-08-15 22:21:10
First-half results…Guangdong-Dongguk-China flight, Jeil-Ildong-Ilyang sales slowdown
The blue light was turned on as domestic pharmaceutical companies generally marched high in the first half.
According to the results of the first half of the year submitted to the Financial Supervisory Service, sales of 34 KOSPI-Kostak domestic pharmaceuticals were 5,576.6 billion won, an 8% increase of 374.9 billion won from 5,201.7 billion won in the same period last year.
In addition, operating profit increased by 62% to 310.1 billion won, an increase of 118.8 billion won from 191.3 billion won in the same period last year. Net profit also increased by 76% to KRW 222.9 billion from KRW 126.5 billion in the same period last year.
However, by company, unlike pharmaceutical companies such as Kwangdong Pharm, Dongkuk Pharm, and Choongwae Pharm, which are running net growth, Jeil Pharm, Ildong Pharm, and Il-yang Pharm have created an atmosphere of slowing down.
First, in terms of sales, Kwangdong Pharmaceutical recorded 732.3 billion won, a 9% increase from 674.1 billion won in the same period last year, showing the highest sales among these pharmaceutical companies. Jeil Pharma Holdings, the holding company, posted 406.3 billion won, down slightly from 408.3 billion won in the same period last year.
On the other hand, Dongkuk Pharm posted sales of 366.7 billion won, up 9% from 335.5 billion won in the same period last year, and JW Pharmaceutical also achieved 354.9 billion won, up 12% from 317.2 billion won in the same period last year, drawing an upward curve.
In addition, Ildong Holdings, the holding company, recorded 319.8 billion won, -6% year-on-year, and Ildong Pharmaceutical recorded 299.4 billion won, -7% year-on-year. 10% growth showed good performance.
In the case of pharmaceutical companies worth 100 billion won, Ilyang Pharm recorded 165.7 billion won, down 2% from the previous year, Hugel 145.9 billion won, 16%, Samjin 143.1 billion won, 12%, SK Biopharmaceuticals 137.8 billion won, 46%, Pharma Research 122.2 billion won, 29%, Pharmaceutical companies excluding Ilyang made a high growth rate, with Anguk Pharm growing 20% with 114.1 billion won, Hana Pharm 9% with 111.5 billion won, and Daehan New Pharm 9% with 104.4 billion won.
JW Life Science 12%, Alico Pharmaceutical 20%, Daehan Pharm 9%, Medytox 6%, Samil 4%, Bukwang 1%, Myungmoon 11%, Humedix 29%, HanAll Bio 40% , Yuyu -2%, JW Shinyak 8%, Dongsung -1%, JW Holdings -9%, Hankook Pharma 11%, Shinil 3%, Ilsung 35%, BC World 10%, showing different growth rates.
Operating profit of Hugel KRW 46.6 billion, Pharma Research KRW 44.4 billion, Sino-foreign KRW 44.2 billion
In terms of operating profit, Hugel posted a record high of 46.6 billion won. However, it was the same as the previous year. Pharma Research ranked 44.4 billion won, JW Pharmaceutical 44.2 billion won, Dongkuk 32.2 billion won, and Huons 29.1 billion won.
In terms of increase and decrease rate, Hanall Biopharma recorded the highest with 6993%, followed by BC World Pharm 413%, Yuyu 134%, JW Heavy Industries 81%, Humedix 73%, Anguk 54%, Guangdong 44%, Alico 40%. business was good Jeil Pharma Holdings, Jeil Pharmaceutical, and Dongsung Pharmaceutical turned to profit, forming a new atmosphere.
In contrast, Ildong Holdings, Ildong Pharmaceutical, SK Biopharmaceuticals, Bukwang, and Ilsung Pharmaceutical were still in the red. Ildong Holdings paid 10.2 billion won in consolation money and Ildong Pharmaceutical paid 9.6 billion won for voluntary retirement that lasted until June.
Samil 2200%, BC World 1158% net profit growth rate ‘giyeom’…everyone continues to lose
In terms of net profit, Hugel recorded 38.4 billion won, leaving other pharmaceutical companies behind. JW Pharmaceutical was followed with 33.7 billion won, Pharma Research 33.5 billion won, Huons 28.7 billion won, Dongkuk 26.4 billion won, Guangdong 24 billion won, Jeil Pharma Holdings 18.3 billion won, Daewon 17.5 billion won, Daehan Pharmaceutical 14.7 billion won, Medytox 14.5 billion won, Humedix 14.4 billion won. , followed by Ilsung New Drug with 14.3 billion won.
In terms of growth rate, Samil Pharm recorded the highest growth at 2200%, followed by BC World Pharm 1158%, JW Jungwae 166%, Guangdong 97%, Huons 77%, Pharma Research 71%, and JW Holdings 65%. Again, Jeil Pharma Holdings, Jeil Pharm, and Hanall Bio turned to the black, while Myungmoon Pharm, JW New Drug, and Korea Pharma turned to the red. Ildong Holdings, Ildong, SK Biopharm, Bukwang, Yuyu, and Dongsung continued to lose money.
© News The Voice Healthcare Unauthorized reproduction and redistribution prohibited
1692142365
#domestic #pharmaceuticals.. #sales #operating #profit #net #profit #growth #blue #light
2023-06-22 14:02:51
Al-Marsad newspaper: The Minister of Hajj and Umrah, Tawfiq Al-Rabiah, announced the reduction of comprehensive insurance from 235 to 88 riyals, by 63%, without changing the existing service and coverage.
He also explained that the ministry has prepared 20 exhibitions and 100 Islamic historical sites during this year’s Hajj season, during the government press conference held with the participation of the Minister of Hajj.
He emphasized the return of the numbers of pilgrims to before the pandemic and the ability of pilgrims to perform the ritual without an upper age limit.
He pointed out that this year’s Hajj is characterized by the lifting of age restrictions, as there are pilgrims over 100 years old.
1687450562
#Minister #Hajj #reveals #good #news #reducing #comprehensive #insurance #pilgrims. #announces #lifting #age #restrictions #AlMarsad #Newspaper